

August 01, 2025

To

Listing Department,

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, Bandra Kurla Complex, Bandra (E),

MUMBAI -400 051

Company Code No. AUROPHARMA

To

The Corporate Relations Department

**BSE LIMITED** 

Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street,

MUMBAI -400 001

Company Code No. 524804

Dear Sir / Madam,

Sub: Clarification / Confirmation on news item appearing in "Media/Publication"

Ref: Your email dated August 1, 2025 seeking clarification on recent news item which appeared in the "Website-www.moneycontrol.com" dated August 01, 2025 captioned "Pharma stocks slump as Trump shoots letters to 17 global drug majors seeking lower prices"

With reference to the above news item and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that: -

Aurobindo Pharma Limited has not received any communication as per the media / publication nor aware of any negotiations / events taking place involving the Company or which could explain the movement in trading of shares of the Company.

In this regard, please note that the Company confirms it is not aware of any price sensitive information which is required to be intimated and has not been intimated to the Stock Exchanges at this point of time as per regulation 30 of the SEBI (LODR) Regulations, 2015.

Please take the information on record.

Yours faithfully,

For AUROBINDO PHARMA LIMITED

B. Adi Reddy Company Secretary

## AUROBINDO PHARMA LIMITED

(CIN: L24239TG1986PLC015190)

www.aurobindo.com

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.